ARTV Artiva Biotherapeutics, Inc. Insider Trading

RA Capital Management bought 21,654 shares at blended avg $8.96; holdings now 16.82M shares at ARTV

RA Capital Management executed 2 separate purchases totaling 21,654 shares for $194,039.82, representing a +0.1% increase to its already substantial 16.82M share position. The blended purchase price of $8.96 sits below the current price of $9.35, and the stock has recovered +9.5% over the last 30 days despite being -35.6% from its 52-week high of $14.53. At this ticker, the insider has made 5 purchases since mid-June (all outcomes currently unmeasurable except one June 12 buy with a +12.5% 30-day return), suggesting continued accumulation during a period of relative price recovery. However, the company remains unprofitable with a -$23.5M net income in the latest quarter and -100.0% annual revenue growth, limiting the strength of any bullish signal from the transaction.

Director RA Capital Management adds 32,876 shares at $8.89 avg amid 5 rapid buys in 16 days; stock +48.8% in 90d.

RA Capital Management, LP filed Form 4 on 2026-06-25 reporting 2 separate purchases totaling 32,876 shares for $292,126.48 at a blended average price of $8.89 per share on 2026-06-25 and 2026-06-26. This transaction is the most recent of 5 consecutive buy transactions by the same director at ARTV executed over a 16-day window (2026-06-10 through 2026-06-25), with holdings expanding from 16.76M to 16.80M shares. Notably, ARTV trades at $9.58 currently, representing +48.8% gains over 90 days and +20.8% over 30 days, though the company is deeply unprofitable (latest quarter revenue of $251.0K, net loss of $-23.5M) and reported -100.0% annual revenue growth. The cross-ticker track record shows RA Capital's prior 20 open-market buys averaged +2.7% 30-day returns, but prior outcomes at ARTV are not yet measurable given the recent timing of all 5 purchases in this cluster.

Director RA Capital Management buys 531,326 shares at $8.66 avg over 3 days despite stock down 8.9% in 30 days; stock still -38.7% from 52-week high.

RA Capital Management filed a Form 4 disclosing 3 separate purchases totaling 531,326 shares for $4,599,903.46 across a three-day window (June 12–16, 2026), with a blended average price of $8.66. The transactions increased the director's holding to 16,763,043 shares from 16,231,717 shares. Notably, this purchase occurred as the stock was trading -38.7% from its 52-week high of $14.53 and down 8.9% over the prior 30 days, though it has rebounded 53.6% over 90 days. The company is unprofitable with a quarterly revenue of $251,000 and full-year net income of -$23,516,000; annual revenue growth is -100.0%, indicating a material revenue decline. The director's prior purchase at ARTV (May 11, 2026) delivered a 90-day return of -30.6%, suggesting this ticker has not aligned with the director's cross-ticker buy success rate (93.33% 90-day win rate across all open-market holdings). The accumulation during a price decline and amid negative fundamentals warrants attention to whether this represents a conviction signal or portfolio mechanics.

RA Capital Management accumulates 1,027,722 shares in 3 purchases (June 9-11) at $7.44 average; stock down -24.7% in 30 days vs. -44.9% from 52-week high.

RA Capital Management, LP filed Form 4 disclosing 3 separate purchases totaling 1,027,722 shares for $7,650,148.29 at a blended average price of $7.44. The insider now holds 16,231,717 shares post-transaction, a +6.8% increase. At current price of $8.00, the stock is -24.7% over 30 days and -44.9% from its 52-week high of $14.53. The company reported latest quarterly revenue of $251,000.00, annual revenue growth of -100.0%, and net income of $-23,516,000.00, indicating a deeply unprofitable position with materially contracted revenue. This accumulation occurs while ARTV trades near mid-range of its 52-week spread and after the insider's prior buy on 2026-05-11 experienced a -35.6% loss over 30 days. The cross-ticker track record shows 93.33% accuracy on prior buys with +5.9% average 30-day returns, but the same-ticker history is unfavorable: 0 of 1 prior buys at ARTV were well-timed at the 90-day mark.

10% Owner GC Corp buys 1,432,291 shares ($16.5M) at $11.52 amid 47.6% decline from 52-week high

GC Corp, a 10% owner at Artiva Biotherapeutics, executed 2 separate purchases totaling 1,432,291 shares (1.43M shares) for $16,499,992.32 ($16.5M) at a blended average price of $11.52, expanding holdings from 175,443 to 1,607,734 shares (+816.4%). The transaction occurs as the stock trades at $7.61, representing a -47.6% decline from the 52-week high of $14.53 and a -16.1% drop over the prior 30 days. The company's fundamentals are strained: latest-quarter revenue totaled $251,000.00 ($251.0K), annual revenue contracted by -100.0%, and net income was negative $-23,516,000.00 ($-23.5M) over the most recent full fiscal year. GC Corp's prior buy activity at this same ticker (2 prior trades on 2024-07-22) both exhibited +1.4% 90-day returns, suggesting a pattern of well-timed entry points at this specific security, though the current substantially lower price level and accelerated cash burn relative to declining revenue represent material context shifts that warrant investor attention.

Ra Capital Management increases stake in ARTV by 75% with ~$75M open-market purchase; first buy at this company in 36 months.

Ra Capital Management, a board director and major shareholder, deployed approximately $75 million to acquire a substantial block of Artiva shares, expanding its indirect stake by more than 75 percent—the largest single acquisition in the fund's 36-month filing history at this company. The purchase occurred while the stock trades well below its 52-week high and follows a dramatic rally over the prior quarter, yet the company remains unprofitable with revenues declining sharply and significant annual net losses. Notably, this represents Ra Capital's first open-market purchase of ARTV shares on record, despite the fund's extensive trading activity across other holdings over the past three years—suggesting a deliberate shift toward this particular investment after a period of inactivity. The timing and scale of the buy are notable given the stock's weak fundamentals, though Ra Capital's prior open-market purchases across its broader portfolio have demonstrated a strong track record of capturing upside gains within 90 days.

Director RA Capital Management bought 8,333,333 shares for $100.0M at $12.00 on IPO day; 4 other insiders also bought within 14 days

RA Capital Management, L.P. executed 2 purchases totaling 8,333,333 shares for $99,999,996.00 at a blended average price of $12.00 on the company's recent listing (4 trading days old). The transaction represents a substantial director-level capital commitment at the IPO offering price. Critically, a cluster pattern is present: 4 other insiders also bought within the past 14 days, indicating coordinated insider accumulation around the initial offering. The current price of $11.80 (as of 2024-07-24) shows minimal deviation from the transaction price, consistent with a newly listed security stabilizing near its opening level.

5AM Partners VI acquired 833,333 shares of ARTV at $12.00 (7/22) in $10.0M purchase amid cluster buy pattern

5AM Partners VI, a 10% owner, purchased 833,333 shares at $12.00 on 2024-07-22 for $9,999,996.00, expanding its holdings from 348,721 shares to 1,182,054 shares—a 239.0% increase. This transaction coincides with a cluster pattern: 4 other insiders also bought within the past 14 days, suggesting coordinated conviction during the company's early post-IPO phase (4 trading days into listing). The current price of $11.80 as of 2024-07-24 reflects slight softening from the transaction price, though 52-week metrics remain uninformative. Note: This filing involves derivative-conversion activity; the insider's full position includes Table II derivative securities not yet populated in this database, so the reported common shares should not be interpreted as the complete post-transaction holdings.

10% owner GC Corp. buys 2,083,332 shares in ARTV for $24,999,984.00 in 2 transactions; cluster buy pattern with 4 other insiders in 14 days

GC Corp., a 10% owner of Artiva Biotherapeutics, executed 2 separate purchases totaling 2,083,332 shares for $24,999,984.00 on 2024-07-22 at $12.00 per share. The transaction occurred within days of the company's recent listing (2 trading days old). This filing reflects a conversion of derivative securities rather than a simple equity purchase, meaning the insider's true position includes both Table I shares (1,260,512 post-transaction) and unconverted derivative holdings not yet visible in this database. Notably, 4 other insiders also purchased shares within the past 14 days, establishing a cluster buy pattern that suggests coordinated confidence in the near-post-IPO window. The scale of this single transaction—nearly $25M at a 10% ownership stake—alongside the broader insider activity warrants attention to how the market prices the business relative to insider acquisition timing.

Director Huh Yong-Jun purchases 2,083,332 shares for $24,999,984.00 at $12.00 in two transactions

Director Huh Yong-Jun executed two purchases totaling 2,083,332 shares for $24,999,984.00 at $12.00 per share on 2024-07-22. This $25.0M purchase is noteworthy given the company's recent listing status (2 trading days old), where the current market price of $11.77 sits slightly below the transaction price. The transaction involves a conversion of derivative securities, meaning the 1,260,512 shares held post-transaction represents only Table I holdings and does not capture the insider's full derivative position. A cluster pattern is present, with 4 other insiders also purchasing within the past 14 days, suggesting coordinated capital deployment during the early public trading period.